Medical management of chronic liver diseases in children (Part I): Focus on curable or potentially curable diseases

Pediatric Drugs

Volumn 13, Issue 6, 2011, Pages 357-370

  El Shabrawi, Mortada H F ^a   Kamal, Naglaa M ^a  

^a CAIRO UNIVERSITY   (Egypt)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR; ALPHA INTERFERON; ALPHA2 INTERFERON; ANTIOXIDANT; ANTIVIRUS AGENT; AZATHIOPRINE; CORTICOSTEROID; CYCLOSPORIN; ENTECAVIR; LAMIVUDINE; NITISINONE; PEGINTERFERON; PEGINTERFERON ALPHA2A; PENICILLAMINE; RIBAVIRIN; TETRATHIOMOLYBDATE AMMONIUM; TRIENTINE; ZINC;

ALOPECIA; AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ANOREXIA; ARTHRALGIA; AUTOIMMUNE DISEASE; AUTOIMMUNE HEPATITIS; BONE MARROW SUPPRESSION; CHRONIC LIVER DISEASE; DEPRESSION; DIETARY INTAKE; DRUG EFFICACY; EARLY DIAGNOSIS; EOSINOPHILIA; FATIGUE; FATTY LIVER; FEVER; FLU LIKE SYNDROME; GALACTOSEMIA; GASTRITIS; GASTROINTESTINAL SYMPTOM; GLYCOGEN STORAGE DISEASE; GOODPASTURE SYNDROME; GROWTH RETARDATION; HAIR LOSS; HEADACHE; HEARING LOSS; HEPATITIS; HEPATITIS B; HEPATITIS C; HEPATOMEGALY; HEREDITARY FRUCTOSE INTOLERANCE; HUMAN; HYPERSENSITIVITY REACTION; HYPERTRIGLYCERIDEMIA; IMMUNOPATHOGENESIS; INSOMNIA; IRON DEFICIENCY ANEMIA; IRRITABILITY; LACTIC ACIDOSIS; LEUKOPENIA; LIVER TOXICITY; LIVER TRANSPLANTATION; NAUSEA; NEPHROTIC SYNDROME; NEUTROPENIA; NONALCOHOLIC FATTY LIVER; OPTIC NEURITIS; PANCREATITIS; PERIPHERAL NEUROPATHY; POLYMYOSITIS; PRIORITY JOURNAL; QUALITY OF LIFE; RASH; REVIEW; SIDE EFFECT; STOMATITIS; SUICIDAL BEHAVIOR; SYSTEMIC LUPUS ERYTHEMATOSUS; TASTE AVERSION; THROMBOCYTOPENIA; TINNITUS; TYROSINEMIA; VERTIGO; VOMITING; WILSON DISEASE;

CARBOHYDRATE METABOLISM, INBORN ERRORS; CHILD; CHILD HEALTH SERVICES; CHRONIC DISEASE; HEPATITIS, CHRONIC; HEPATOLENTICULAR DEGENERATION; HUMANS; QUALITY OF LIFE; TREATMENT OUTCOME;

EID: 80054762048     PISSN: 11745878     EISSN: 11792019     Source Type: Journal    
DOI: 10.2165/11591610-000000000-00000     Document Type: Review

References (120)

1. El-Shabrawi MHF, Kamal NM. Medical management of chronic liver diseases (CLD) in children (part II): focus on the complications of CLD, and CLD that require special considerations. Pediatr Drugs 2011; 13 (6): 371-83
2. Elsas LJ. Galactosemia. In: Pagon RA, Bird TD, Dolan CR, et al., editors. GeneReviews. Seattle (WA): University of Washington, Seattle, 1993-2000 Feb 4 [updated 2010 Oct 26]
3. Elsas LJ. Prenatal diagnosis of galactose-1-phosphate uridyltransferase (GALT)-deficient galactosemia. Prenat Diagn 2001; 21: 302-3 (Pubitemid 32417216)
4. Zlatunich CO, Packman S. Galactosaemia: early treatment with an elemental formula. J Inherit Metab Dis 2005; 28: 163-8 (Pubitemid 40723884)
5. Berry GT, Moate PJ, Reynolds RA, et al. The rate of de novo galactose synthesis in patients with galactose-1-phosphate uridyltransferase deficiency. Mol Genet Metab 2004; 81: 22-30 (Pubitemid 38064429)
6. Bosch AM, Bakker HD, Wenniger-Prick LJ, et al. High tolerance for oral galactose in classical galactosaemia: dietary implications. Arch Dis Child 2004; 89: 1034-6
7. Schadewaldt P, Kamalanathan L, Hammen HW, et al. Age dependence of endogenous galactose formation in Q188R homozygous galactosemic patients. Mol Genet Metab 2004; 81: 31-44 (Pubitemid 38064430)
8. Elsas L, Acosta P. Nutritional support of inherited metabolic disease. In: Shils M, Olson J, Shike M, et al., editors. Modern nutrition in health and disease. 9th ed. Baltimore (MD): Williams & Wilkins, 1998: 1003-56
9. Elsas LJ, Acosta PB. Inherited metabolic disease: aminoacids, organic acids and galactose. In: Shils ME, Shike M, Ross AC, et al., editors. Modern nutrition in health and disease. 10th ed. Philadelphia (PA): Lippincott Williams & Wilkins, 2006: 909-59
10. Hardy S, Kleinman RE. Cirrhosis and chronic liver failure. In: Suchy FJ, Sokol RJ, Balistreri WF, editors. Liver disease in children. 3rd ed. New York: Cambridge University Press, 2007: 97-137
11. Panis B, Vermeer C, van Kroonenburgh MJ, et al. Effect of calcium, vitamins K1 and D3 on bone in galactosemia. Bone 2006; 39: 1123-9 (Pubitemid 44528377)
12. Menezo YJ, Lescaille M, Nicollet B, et al. Pregnancy and delivery after stimulation with rFSH of a galatosemia patient suffering hypergonadotropic hypogonadism: case report. J Assist Reprod Genet 2004; 21: 89-90 (Pubitemid 39023455)
13. Rubio-GozalboM, Gubbels C, Bakker J, et al. Gonadal function in male and female patients with classic galactosemia. Hum Reprod Update 2010; 16: 177-88
14. Tang M, Wierenga K, Elsas LJ, et al. Molecular and biochemical characterization of human galactokinase and its small molecule inhibitors. Chem Biol Interact 2010 Dec 5; 188 (3): 376-85
15. Ghishan FK, Zawaideh M. Inborn errors of carbohydrate metabolism. In: Suchy FJ, Sokol RJ, Balistreri WF, editors. Liver disease in children. 3rd ed. New York: Cambridge University Press, 2007: 595-625
16. Nordlie RC. Fine tuning of blood glucose concentrations. Trends Biochem Sci 1985; 10: 70-5 (Pubitemid 15166745)
17. Chen YT. Glycogen storage diseases. In: Scriver CR, Beaudet AL, Sly WS, et al., editors. The metabolic and molecular bases of inherited disease. 8th ed. New York: McGraw-Hill, 2001: 1521-51
18. ChenYT.Glycogen storage disease and other inherited disorders of carbohydrate metabolism. In: Kasper DL, Braunwald E, Fauci A, et al., editors. Harrisons principles of internal medicine. 16th ed. New York: McGraw-Hill, 2004
19. Chen YT, Bali DS. Glycogen storage diseases. In: Fuchs J, PoddaM, editors. Encyclopedia of diagnostic genomics and proteomics. New York: Marcel Dekker Inc, 2004: 543-9
20. Matern D, Seydewitz HH, Bali D, et al. Glycogen storage disease type I: diagnosis and phenotype/genotype correlation. Eur J Pediatr 2002; 161 Suppl. 1: S10-9
21. Hiraiwa H, Pan CJ, Lin B, et al. Inactivation of the glucose 6-phosphate transporter causes glycogen storage disease type 1b. J Biol Chem 1999; 274: 5532-6 (Pubitemid 29109201)
22. Rake JP, Visser G, Labrune P, et al. Guidelines for management of glycogen storage disease type I: European Study on Glycogen Storage Disease Type I (ESGSD I). Eur J Pediatr 2002; 161: 112-9
23. Rake JP, Visser G, Labrune P, et al. Glycogen storage disease type I: diagnosis, management, clinical course and outcome. Results of the European Study on Glycogen Storage Disease Type I (ESGSD I). Eur J Pediatr 2002; 161 Suppl. 1: S20-34
24. Veiga-da-Cunha M, Gerin I, Chen YT, et al. A gene on chromosome 11q23 coding for a putative glucose- 6-phosphate translocase is mutated in glycogen- storage disease types Ib and Ic. Am J Hum Genet 1998; 63: 976-83 (Pubitemid 30418566)
25. Ekstein J, Rubin BY, Anderson SL, et al. Mutation frequencies for glycogen storage disease Ia in the Ashkenazi Jewish population. Am J Med Genet A 2004; 129A: 162-4 (Pubitemid 39121283)
26. Chou JY, Matern D, Mansfield BC, et al. Type I glycogen storage diseases: disorders of the glucose-6-phosphatase complex. Curr Mol Med 2002; 2: 121-43 (Pubitemid 34649836)
27. Bali DS, Chen YT, Goldstein JL. Glycogen storage disease type I. In: Pagon RA, Bird TD, Dolan CR, et al., editors. GeneReviews. Seattle (WA): University of Washington, Seattle, 1993-2006 Apr 19 [updated 2010 Dec 23]
28. SchwenkWF, HaymondMW. Optimal rate of enteral glucose administration in children with glycogen storage disease type I. N Engl J Med 1986; 314: 682-5 (Pubitemid 16164098)
29. Ghishan FK, Greene HL. Inborn errors of metabolism that cause permanent injury to the liver. In: Zakim D, Boyer T, editors. Hepatology: a textbook of liver disease. 2nd ed. Philadelphia (PA): WB Saunders, 1990; 49: 1300-48
30. Chen Y-T, Cornblath M, Sidbury JB. Cornstarch therapy in type I glycogen storage disease. N Engl J Med 1984; 310: 171-5 (Pubitemid 14224111)
31. Wolfsdorf JI, Crigler JF. Effect of continuous glucose therapy began in infancy on the long-term clinical course of patients with type I glycogen storage disease. J Pediatr Gastroenterol Nutr 1999; 29: 136-43 (Pubitemid 30366162)
32. Weinstein DA, Wolfsdorf JI. Effect of continuous glucose therapy with uncooked cornstarch on the long-term clinical course of type 1a glycogen storage disease. Eur J Pediatr 2002; 161 Suppl. 1: S35-9
33. Weinstein DA, Somers MJ, Wolfsdorf JI. Decreased urinary citrate excretion in type 1a glycogen storage disease. J Pediatr 2001; 138: 378-82 (Pubitemid 32207141)
34. Wolfsdorf JI, Weinstein DA. Glycogen storage diseases. Rev Endocr Metab Disord 2003; 4: 95-102 (Pubitemid 36182154)
35. Myrup B, Valerius NH, Mortensen PB. Treatment of enteritis in chronic granulomatous disease with granulocyte colony stimulating factor. Gut 1998; 42: 127-30 (Pubitemid 28228401)
36. Visser G, Rake JP, Fernandes J, et al. Neutropenia, neutrophil dysfunction, and inflammatory bowel disease in glycogen storage disease type Ib: results of the European Study on Glycogen Storage Disease type I. J Pediatr 2000; 137: 187-91 (Pubitemid 30659225)
37. Calderwood S, Kilpatrick L, Douglas SD, et al. Recombinant human granulocyte colony-stimulating factor therapy for patients with neutropenia and/or neutrophil dysfunction secondary to glycogen storage disease type 1b. Blood 2001; 97: 376-82 (Pubitemid 32060320)
38. Steinmetz BA, Martin MG, Roberts RL. Granulocyte-macrophage colonystimulating factor for treating gastrostomy tube site healing in a child with glycogen storage disease type Ib. J Pediatr Gastroenterol Nutr 2001; 33: 94-6 (Pubitemid 32706134)
39. Visser G, Rake JP, Labrune P, et al. Consensus guidelines for management of glycogen storage disease type 1b-European Study on Glycogen Storage Disease Type 1. Eur J Pediatr 2002; 161: 120-3
40. Bhattacharya K, Orton RC, Qi X, et al. A novel starch for the treatment of glycogen storage diseases. J Inherit Metab Dis 2007; 30: 350-7 (Pubitemid 46881681)
41. Yiu WH, Pan CJ, Allamarvdasht M, et al. Glucose-6-phosphate transporter gene therapy corrects metabolic and myeloid abnormalities in glycogen storage disease type Ib mice. Gene Ther 2007; 14: 219-26 (Pubitemid 46152625)
42. Dagli AI, Weinstein DA. Glycogen storage disease type VI. In: Pagon RA, Bird TC, Dolan CR, et al., editors. GeneReviews. Seattle (WA): University of Washington, Seattle, 1993-2009 Apr 23 [updated 2011 May 17]
43. Bell L, Sherwood WG. Current practices and improved recommendations for treating hereditary fructose intolerance. J Am Diet Assoc 1987; 87: 721-30 (Pubitemid 17088957)
44. Fox IH, Kelley WN. Studies on the mechanism of fructose induced hyperuricemia in man. Metabolism 1972; 21: 713-21
45. Narins RG, Weisberg JS, Myers AR. Effects of carbohydrates on uric acid metabolism. Metabolism 1974; 23: 455-65
46. Heuckenkamp P-U, Zollner N. Fructose-induced hyperuricaemia. Lancet 1971; II: 808-9
47. Sahebjami H, Scalettar R. Effects of fructose infusion on lactate and uric acid metabolism. Lancet 1971; I: 366-9
48. Levin B, Snodgrass GJ, Oberholzer VG, et al. Fructosaemia: observations on seven cases. Am J Med 1968; 45: 826-38
49. Cornblath M, Rosenthal IM, Reisner SH, et al. Hereditary fructose intolerance. N Engl J Med 1963; 269: 1271-8
50. Froesch ER, Wolf HP, Baitsch H, et al. Hereditary fructose intolerance: an inborn defect of hepatic fructose-1-phosphate splitting aldolase. Am J Med 1963; 34: 151-67
51. Perheentupa J, Raivio KO, Nikkila EA. Hereditary fructose intolerance. Acta Med Scand 1972; 542 Suppl.: 65-75
52. Bouteldja N, Timson DJ. The biochemical basis of hereditary fructose intolerance. J Inherit Metab Dis 2010 Apr; 33 (2): 105-12
53. Anderson TA. Recent trends in carbohydrate consumption. Annu Rev Nutr 1982; 2: 113-32
54. Gitzelmann R, Steinmann B, Van den Berghe G. Disorders of fructose metabolism. In: Stanbury JB, Wyngaarden JB, Fredrickson DS, editors. The metabolic basis of inherited disease. 6th ed. New York: McGraw-Hill, 1989: 399-424
55. Oberhaensli RD, Rajagopalan B, Taylor DJ, et al. Study of hereditary fructose intolerance by use of 31P magnetic resonance spectroscopy. Lancet 1987; II: 931-7
56. Mock DM, Perman JA, Thaler MM, et al. Chronic fructose intoxication after infancy in children with hereditary fructose intolerance: a cause of growth retardation. N Engl J Med 1983; 309: 764-70 (Pubitemid 13004285)
57. Shallenberger RS. Occurrence of various sugars in foods. In: Sipple HL, McNutt KW, editors. Sugars in nutrition. New York: Academic Press, 1974: 67-80
58. Hardinge MG, Swarner JB, Crooks H. Carbohydrates in foods. J Am Diet Assoc 1965; 46: 197-204
59. Somogyi JC, Trautner K. Der Glukose-, Fructose- und Saccharosegehalt verschiedener Gemusearten. Schweiz MedWochenschr 1974; 104: 177-82
60. Wyke RJ, Rajkovic IA, Eddleston AL, et al. Defective opsonization and complement deficiency in serum from patients with fulminant hepatic failure. Gut 1980; 21: 643-9 (Pubitemid 10020935)
61. Odievre M, Gentil C, Gautier M, et al. Hereditary fructose intolerance in childhood. Am J Dis Child 1978; 132: 605-8
62. Carey RG, Balistreri WF. Metabolic diseases of the liver. In: Kliegman RM, Behrman RE, Jenson HB, et al., editors. Nelson textbook of pediatrics. 18th ed. Philadelphia (PA): Saunders Elsevier, 2008: 1675-80
63. Cox DW, Roberts E. Wilson Disease. In: Pagon RA, Bird TC, Dolan CR, et al., editors. GeneReviews. Seattle (WA): University of Washington, Seattle, 1993-1999 Oct 22 [updated 2006 Jan 24]
64. Farber M, Knuppel RA, Binkiewicz A, et al. Pregnancy and von Gierkes disease. Obstet Gynecol 1976; 47: 226-8
65. Brewer GJ, Yuzbasiyan-Gurkan V, Dick R, et al. Does a vegetarian diet control Wilsons disease? J Am Coll Nutr 1993 Oct; 12 (5): 527-30 (Pubitemid 23289838)
66. Roberts EA, Schilsky ML. A practice guideline on Wilson disease. Hepatology 2003; 37: 1475-92 (Pubitemid 36667330)
67. Koeberl DD, Pinto C, Sun B, et al. AAV vector-mediated reversal of hypoglycemia in canine and murine glycogen storage disease type Ia. Mol Ther 2008; 16: 665-72 (Pubitemid 351426167)
68. OConnor JA, Sokol RJ. Copper metabolism and copper storage disease. In: Suchy FJ, Sokol RJ, Balistreri WF, editors. Liver disease in children. 3rd ed. New York: Cambridge University Press, 2007: 626-60
69. Schilsky ML, Scheinberg IH, Sternlieb I. Liver transplantation for Wilsons disease: indications and outcome. Hepatology 1994; 19: 583-7 (Pubitemid 24066886)
70. Emre S, Atillasoy EO, Ozdemir S, et al. Orthotopic liver transplantation for Wilsons disease: a single-center experience. Transplantation 2001; 72: 1232-6 (Pubitemid 33026600)
71. Sutcliffe RP, Maguire DD, Muiesan P, et al. Liver transplantation for Wilsons disease: long-term results and quality-of-life assessment. Transplantation 2003; 75: 1003-6 (Pubitemid 36442687)
72. Merja A, Sari P, Matti KS, et al. Current strategies for the treatment of hereditary tyrosinemia type I. Pediatr Drugs 2006; 8 (1): 47-54
73. Sniderman King L, Trahms C, Scott CR. Tyrosinemia type 1. In: Pagon RA, Bird TC, Dolan CR, et al., editors. GeneReviews. Seattle (WA): University of Washington, Seattle, 1993-2006 Jul 24 [updated 2008 Oct 21]
74. Mitchell GA, Rezvani I. Tyrosine. In: KliegmanRM, BehrmanRE, JensonHB, et al., editors. Nelson textbook of pediatrics. 18th ed. Philadelphia (PA): Saunders Elsevier, 2008
75. El-Karaksy H, Rashed M, El-Sayed R, et al. Clinical practice. NTBC therapy for tyrosinemia type 1: how much is enough? Eur J Pediatr 2010 Jun; 169 (6): 689-93
76. Musso G, Gambino R, Cassader M. Non-alcoholic fatty liver disease from pathogenesis to management: an update. Obes Rev 2010 Jun; 11 (6): 430-45
77. Xanthakos SA, Balistreri WF. Liver disease associated with systemic disorders. In: Kliegman RM, Behrman RE, Jenson HB, et al., editors. Nelson textbook of pediatrics. 18th ed. Philadelphia (PA): Saunders Elsevier, 2008
78. Federico A, Niosi M, Vecchio Blanco CD, et al. Emerging drugs for nonalcoholic fatty liver disease. Expert Opin Emerg Drugs 2008 Mar; 13 (1): 145-58 (Pubitemid 351448707)
79. Portincasa P, Grattagliano I, Palmieri VO, et al. Current pharmacological treatment of nonalcoholic fatty liver. Curr Med Chem 2006; 13 (24): 2889-900 (Pubitemid 44509714)
80. Marchesini G, Brizi M, Bianchi G, et al. Metformin in non-alcoholic steatohepatitis. Lancet 2001; 358 (9285): 893-4 (Pubitemid 32900577)
81. Nair S, Diehl AM, Wiseman M, et al. Metformin in the treatment of nonalcoholic steatohepatitis: a pilot open label trial. Aliment Pharmacol Ther 2004; 20 (1): 23-8 (Pubitemid 38938715)
82. Angelico F, Burattin M, Alessandri C, et al. Drugs improving insulin resistance for non-alcoholic fatty liver disease and/or non-alcoholic steatohepatitis. Cochrane Database Syst Rev 2007; (1): CD005166
83. Socha P, Horvath A, Vajro P, et al. Pharmacological interventions for nonalcoholic fatty liver disease in adults and in children: a systematic review. J Pediatr Gastroenterol Nutr 2009; 48 (5): 587-96
84. Trappoliere M, Tuccillo C, Federico A, et al. The treatment of NAFLD. Eur Rev Med Pharmacol Sci 2005 Sep-Oct; 9 (5): 299-304 (Pubitemid 41387396)
85. Trappoliere M, Federico A, Tuccillo C, et al. Effects of a new pharmacological complex (silybin + vitamin-E + phospholipids) on some markers of the metabolic syndrome and of liver fibrosis in patients with hepatic steatosis. Preliminary study. Minerva Gastroenterol Dietol 2005 Jun; 51 (2): 193-9 (Pubitemid 44251911)
86. Cuestas ML, Mathet VL, Oubiña JR, et al. Drug delivery systems and liver targeting for the improved pharmacotherapy of the hepatitis B virus (HBV) infection. Pharm Res 2010 Jul; 27 (7): 1184-202
87. Doerig C, Antonino A, Pache I, et al. Management of chronic hepatitis B [in French]. Rev Med Suisse 2010 Jan 27; 6 (233): 168-70, 172-3
88. Balsano C, Alisi A. Viral hepatitis B: established and emerging therapies. Curr Med Chem 2008; 15 (9): 930-9 (Pubitemid 351736414)
89. Shah U, Kelly D, Chang MH, et al. Management of chronic hepatitis B in children. J Pediatr Gastroenterol Nutr 2009 Apr; 48 (4): 399-404
90. Chang MH. Natural history and clinical management of chronic hepatitis B virus infection in children. Hepatol Int 2008 May; 2 Suppl. 1: 28-36
91. Hochman JA, Balistreri WF. Acute and chronic viral hepatitis. In: Suchy FJ, Sokol RJ, Balistreri WF, editors. Liver disease in children. 3rd ed. New York: Cambridge University Press, 2007: 369-446
92. Liaw Y-F, the ACT-HBV Asia Pacific Steering Committee Members. Chronic hepatitis B: treatment alert. Liver Int 2006; 26: 47-58 (Pubitemid 44697935)
93. Liaw YF, Leung N, Guan R, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2005 update. Liver Int 2005; 25: 472-89 (Pubitemid 40861895)
94. Lok AS, McMahon BJ. Chronic hepatitis B (AASLD practice guidelines). Hepatology 2001; 34: 1225-41
95. Anand AC, Puri P. Treatment of chronic hepatitis B: will entecavir and telbivudine do the trick? Trop Gastroenterol 2008 Apr-Jun; 29 (2): 71-5
96. Yazigi N, Balistreri WF. Viral hepatitis. In: Kliegman RM, Behrman RE, Jenson HB, et al., editors. Nelson textbook of pediatrics. 18th ed. Philadelphia (PA): Saunders Elsevier, 2008
97. Sokal E. Drug treatment of pediatric chronic hepatitis B. Paediatr Drugs 2002; 4 (6): 361-9 (Pubitemid 34651925)
98. Susan KJ, Lesley SJ. Lamivudine: in children and adolescents with chronic hepatitis B virus infection. Pediatr Drugs 2002; 4 (10): 687-94
99. Keeffe EB, Dieterich DT, Pawlotsky JM, et al. Chronic hepatitis B: preventing, detecting, and managing viral resistance. Clin Gastroenterol Hepatol 2008 Mar; 6 (3): 268-74 (Pubitemid 351324881)
100. Neely MN, Rakhmanina NY. Pharmacokinetic optimization of antiretroviral therapy in children and adolescents.ClinPharmacokinet 2011Mar 1; 50 (3): 143-89
101. Lee C, Custer JW, Rau RE. Formulary: penicillamine. In: Custer JW, Rau RE, editors. The Harriet Lane handbook, 18th ed. Philadelphia (PA): Mosby Elsevier, 2008: 938-9
102. Vcev A. Management of side effects during antiviral therapy. Acta Med Croatica 2009 Dec; 63 (5): 463-7
103. Fontana RJ, Keeffe EB, Carey W, et al., for the National Institutes of Health Hepatitis B Virus Orthotopic Liver Transplantation Study Group. Effect of lamivudine treatment on survival of 309NorthAmerican patients awaiting liver transplantation for chronic hepatitis B. Liver Transpl 2002 May; 8 (5): 433-9 (Pubitemid 34520771)
104. Adusumilli S. Tenofovir disoproxil fumarate for the treatment of hepatitis B infection. Drugs Today (Barc) 2009 Sep; 45 (9): 679-85
105. Duong A, Mousa SA. Current status of nucleoside antivirals in chronic hepatitis B. Drugs Today (Barc) 2009 Oct; 45 (10): 751-61
106. Jonas MM, Kelly D, Pollack H, et al. Safety, efficacy, and pharmacokinetics of adefovir dipivoxil in children and adolescents (age 2 to <18 years) with chronic hepatitis B Hepatology 2008 Jun; 47 (6): 1863-71. (Pubitemid 351945554)
107. Sokal EM, Kelly D, Wirth S, et al. The pharmacokinetics and safety of adefovir dipivoxil in children and adolescents with chronic hepatitis B virus infection. J Clin Pharmacol 2008 Apr; 48 (4): 512-7 (Pubitemid 351389107)
108. Mubareka S, Leung V, Aoki FY, et al. Famciclovir: a focus on efficacy and safety. Expert Opin Drug Saf 2010 Jul; 9 (4): 643-58
109. Borgia G, Gentile I. Treating chronic hepatitis B: today and tomorrow. Curr Med Chem 2006; 13 (23): 2839-55 (Pubitemid 44509728)
110. Mao HY, Shi TD. Treatment with interferon and thymosin alpha-1 versus interferon monotherapy for HBeAg positivie chronic hepatitis B: a meta analysis [in Chinese]. Zhonghua Gan Zang Bing Za Zhi 2011 Jan; 19 (1): 29-33
111. Galoppo M, Galoppo C. Management of hepatitis C virus infection in childhood. Ann Hepatol 2010; 9 Suppl.: 98-102
112. Davison SM, Kelly DA. Management strategies for hepatitis C virus infection in children. Paediatr Drugs 2008; 10 (6): 357-65
113. Lee C, Custer JW, Rau RE. Formulary: ribavirin. In: Custer JW, Rau RE, editors. The Harriet Lane handbook. 18th ed. Philadelphia (PA): Mosby Elsevier, 2008: 975-6
114. Garg G, Kar P. Management of HCV infection: current issues and future options. Trop Gastroenterol 2009 Jan-Mar; 30 (1): 11-8
115. Cross TJ, Antoniades CG, Harrison PM. Current and future management of chronic hepatitis C infection. Postgrad Med J 2008 Apr; 84 (990): 172-6 (Pubitemid 351600788)
116. Rai R, Deval J. New opportunities in anti-hepatitis C virus drug discovery: targeting NS4B. Antiviral Res 2011 May; 90 (2): 93-101
117. Lee C, Custer JW, Rau RE. Formulary: azathioprine. In: Custer JW, Rau RE, editors. The Harriet Lane Handbook. 18th ed. Philadelphia (PA): Mosby Elsevier, 2008: 742-3
118. Strassburg CP, Manns MP. Treatment of autoimmune hepatitis. Semin Liver Dis 2009 Aug; 29 (3): 273-85
119. Sherman KE, Narkewicz M, Pinto PC. Cyclosporine in the management of corticosteroid-resistant type I autoimmune chronic active hepatitis. J Hepatol 1994 Dec; 21 (6): 1040-7
120. El-Shabrawi M, Wilkinson ML, Portmann B, et al. Primary sclerosing cholangitis in childhood. Gastroenterology 1987 May; 92 (5 Pt 1): 1226-35 (Pubitemid 17055913)